Solabegron

DB06190InvestigationalSmall molecule

Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.

Chemical structure of Solabegron
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in diabetes mellitus type 2, irritable bowel syndrome (IBS), and urinary incontinence.Curator reviewed
Formula / weight
C23H23ClN2O3 · 410.9 g/mol (avg)
Code names
GW 427353

Resolves to

Compound
UNII55P6YH9O6NCAS252920-94-8ChEMBLCHEMBL208427ChEBI141346PubChem9887812
Structure
InChIKeyLLDXOPKUNJTIRF-QFIPXVFZSA-NSMILES[H][C@](O)(CNCCNC1=CC(=CC=C1)C1=CC(=CC=C1)C(O)=O)C1=CC=CC(Cl)=C1
Targets
P13945ADRB3

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
673Drug interactionsStructured to mechanism, not free text
Sign in
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
9+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Solabegron, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In